AngioDynamics, Inc.
ANGO · Price history
Price at last available close
$12.13
−$3.41 (-21.94%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About AngioDynamics, Inc.
Primary reporting period: 2026-05-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets. The company's portfolio includes advanced ablation systems like NanoKnife, designed for the precise surgical removal of soft tissues, and Solero microwave and radiofrequency systems, effective in ablating solid cancerous or benign growths.
How they make money
AngioDynamics designs, manufactures, and sells medical devices for vascular access, peripheral vascular disease, and oncology. The company generates revenue primarily through the direct sale of these medical devices to hospitals, outpatient clinics, and other healthcare providers, supported by a clinical and regulatory-focused R&D strategy.
Products & services
Medical devices including vascular access products, peripheral vascular disease solutions, and oncology/surgery products such as the NanoKnife system.
Brands & revenue mix
Irreversible electroporation system for oncology and surgery.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
Customer concentration
The company does not have any single customer that accounts for 10% or more of its total net revenue for the fiscal year ended May 31, 2026.
Suppliers, materials & equipment
- Contract Manufacturers — The company utilizes various third-party contract manufacturers for components and finished goods; specific supplier names are not disclosed.Source
Business relationships & partnerships
Competitors
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
25
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
34
Poor
Financial Strength
65
Business Quality / Moat
10
Management
40
Growth Quality
25
Risk / Durability
5
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
29
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
38/100
Building Historical Record
Model Score 38/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Balance-sheet / debt profile scores strongly
- •Debt service risk
- •M&A headline · Sep 3, 2026
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for ANGO
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can ANGO maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is ANGO's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •How is ANGO likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for ANGO to reach sustainable profitability?
- •What future growth or profitability would be needed to justify ANGO's current valuation?
Essential Investment Snapshot
Wall Street Score
25
Opportunity Score
29
Market Cap
$510.1M
P/E Ratio
-14.2
EPS
$-0.79
52-Week High
$16.29
52-Week Low
$9.39
Beta
0.30
Analyst Target
$19.50
Shares Outstanding
41.5M
Total Revenue
$325.4M
Total Debt
$0
Dividend
No current dividend
Liquidation Value / Share
$3.95
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Extreme movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for ANGO
Detected from reported data — verify before acting.Debt service risk
Interest coverage is low (~-133.5x). Earnings may be strained to cover interest expense.
M&A headline · Sep 3, 2026
32,900 Shares in AngioDynamics, Inc. $ANGO Acquired by Canada Pension Plan Investment Board — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
Defense WorldCommunity Sentiment
0 active · 0 total callsNo personal call yet on ANGO.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Innovative R&D pipeline.
- +Clinical and regulatory pathway expansion.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Instruments & Supplies industry.
- −Dependence on third-party suppliers and contract manufacturers.
- −Regulatory compliance and clinical trial outcomes.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
9 historical score records availablePrevious Score
25
Oct 8, 2026
Change
+0.6
points
Current Score
25
Oct 9, 2026
Category Changes
ANGO increased 0.6 points because Revenue improved by 3.1 points, Asset improved by 2.1 points.
Positive Contributors
- + Revenue improved by 3.1 points
- + Asset improved by 2.1 points
Projected Score
Projected Score
23
Projected Change
-2.2 points
Preliminary comparable-period financial changes suggest decline of approximately 2.2 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$12.13
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $325.4M | $320.2M | $292.5M | $303.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $144.3M | $145.3M | $134.8M | $149.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $181.1M | $174.9M | $157.7M | $154.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $31.0M | $29.4M | $26.2M | $31.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $158.9M | $157.1M | $145.2M | $144.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $212.7M | $214.8M | $197.7M | $347.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$10.6M | $488K | $1.7M | -$6.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$31.7M | -$39.9M | -$40.0M | -$192.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $207K | $299K | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$32.8M | -$36.3M | -$34.0M | -$191.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $178K | $442K | -$39K | -$7.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$32.9M | -$36.7M | -$34.0M | -$184.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-0.79 | $-0.88 | $-0.83 | $-4.59 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 42.02M | 41.53M | 40.98M | 40.18M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 42.02M | 41.53M | 40.98M | 40.18M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$80.9M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.17
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-100.0%
Cash Change
-12.4%
Margin Change
+5.6 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Debt reduced
What Weakened
- Cash position declined
Potential Score Impact
Positive indicators included revenue growth, debt levels, net income margin. Pressure indicators included EPS growth, cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 6.9%. EPS declined 34.6%. Cash declined 12.4%. Total debt declined 100.0%. Net income margin improved by 5.6 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
9 historical recordsHistorical Score Chart
3 of 9 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - Instruments & SuppliesNews
AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer
AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer
ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y
AngioDynamics Stock Is Falling Thursday: What's Going On?
Rumor Mill · ANGO
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial